Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesPacific Edge Ltd

Pacific Edge Ltd

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.215 AUD -0.02 ( 8.51%)
Last update at 2026-11-11T04:44:00Z
VOLUME
264551
Market Cap
235.96M

Momentum Score

…

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients; Cxbladder Detect, which improve practice workflow and efficiency in urological care; Cxbladder Triage Plus, a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in patients; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a recurrent non-muscle invasive bladder cancer. In addition, the company is developing products for bladder, gastric, colorectal and endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.21
Low
0.23
High
52 Week Price Range
0.12
Low
0.27
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Pacific Edge Ltd develops and commercial non‑invasive cancer diagnostics, principally the urine‑based Cxbladder tests for bladder cancer, with commercial and clinical activities in the United States and other markets. Long‑term growth may be supported by wider clinical adoption, additional clinical validation and geographic expansion, and the company appears positioned to benefit from a broader shift toward less invasive diagnostic testing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.23
Dividend Yield
-
Revenue TTM
13.01M
Revenue Per Share
0.01
Gross Profit TTM
1.41M
Debt / Equity
0.12
ROE
-194.74%
Net Debt
-6.54M
ROCE
-350.84%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -37.52M -29.94M -29.54M -26.96M -19.79M
Net income -36.04M -29.94M -32.20M -26.96M -19.79M
Selling general administrative - 5.80M 5.54M 5.99M 4.05M
Selling and marketing expenses - 17.53M 25.59M 25.12M 14.28M
Gross profit -0.94M 21.85M 13.48M 10.27M 4.95M
Reconciled depreciation - 2.34M 2.40M 1.62M 0.39M
Ebit -38.11M -34.10M -39.50M -34.41M -22.19M
Ebitda -35.48M -31.76M -37.10M -32.80M -21.80M
Depreciation and amortization 2.63M 2.34M 2.40M 1.62M 0.39M
Operating income -38.11M -34.10M -45.92M -34.41M -22.19M
Other operating expenses 49.70M 55.95M 71.15M 54.03M 33.63M
Interest expense 0.02M - 0.02M - -
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 1.93M 3.74M 2.76M 0.55M
Net interest income - 1.89M 3.72M 2.75M 0.53M
Income tax expense -1.48M - -5.18M -3.70M -0.51M
Total revenue 11.58M 21.85M 25.23M 19.62M 11.45M
Total operating expenses 37.17M 55.95M 59.40M 54.03M 33.63M
Cost of revenue 12.53M 12.49M 11.75M 9.35M 6.50M
Total other income expense net 0.60M 4.17M 16.38M 3.75M 1.88M
Net income from continuing ops - -29.94M -32.20M -26.96M -19.79M
Net income applicable to common shares - - - - -19.79M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 17.73M 37.03M 65.45M 97.12M 124.03M
Intangible assets 0.43M 0.78M 0.95M 1.03M 0.43M
Other current assets 1.51M 0.44M 1.23M 0.24M 0.17M
Total liab 6.99M 10.95M 10.83M 8.71M 7.43M
Total stockholder equity 10.74M 26.09M 54.62M 88.41M 116.60M
Deferred long term liab - - - - 0.01M
Other current liab 4.28M - 8.02M 5.28M 3.54M
Common stock 316.44M - 294.40M 294.32M 294.14M
Capital stock - 294.46M - 294.32M 294.14M
Retained earnings -314.15M -276.22M -246.35M -216.81M -189.85M
Other assets - - - - 0.01M
Cash 7.83M 22.57M 29.26M 77.79M 105.41M
Total current liabilities 6.87M 9.76M 8.32M 8.27M 6.51M
Net debt -6.54M - -26.45M -76.57M -103.49M
Short term debt 1.17M - 0.30M 0.81M 1.07M
Short long term debt - 0.30M - - -
Short long term debt total 1.29M - 2.81M 1.22M 1.92M
Other stockholder equity - - - 5.65M 8.22M
Property plant equipment - - - - 3.23M
Total current assets 13.87M 30.82M 57.88M 91.84M 120.08M
Net tangible assets - - - - 107.95M
Short term investments - - 21.00M - -
Net receivables 2.48M 2.83M 4.70M 5.49M 4.01M
Inventory 2.05M 1.61M 1.69M 1.29M 1.01M
Accounts payable 1.42M 2.64M - 2.18M 1.91M
Accumulated other comprehensive income 8.44M - 6.57M 5.26M 4.09M
Non currrent assets other - - -0.00M 0.34M 0.28M
Non current assets total 3.86M 6.21M 7.57M 5.28M 3.95M
Capital lease obligations - 2.60M - 1.22M 1.92M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments - 6.70M 24.19M 22.47M -52.13M
Change to liabilities - - - 1.95M 1.79M
Total cashflows from investing activities 13.05M 6.70M 22.19M - -52.13M
Net borrowings - - 0.30M - -1.15M
Total cash from financing activities 17.61M -1.64M -1.11M -1.28M 100.66M
Change to operating activities - - - -2.33M -0.19M
Net income -36.04M -29.94M -29.54M -26.96M -19.79M
Change in cash -2.60M -19.78M -3.97M -2.18M 31.28M
Begin period cash flow 10.43M 29.26M 36.22M 35.41M 4.13M
End period cash flow 7.83M 9.48M 31.90M 33.23M 35.41M
Total cash from operating activities -32.17M -24.74M -25.75M -25.57M -17.55M
Issuance of capital stock - - - 0.00M 105.79M
Depreciation 2.63M - 2.04M 1.77M 1.39M
Other cashflows from investing activities - -0.35M -2.66M - -
Dividends paid - - - - 1.15M
Change to inventory -0.44M 0.08M -0.40M -0.28M -0.22M
Change to account receivables 2.78M -0.58M 0.96M -1.64M -1.77M
Sale purchase of stock - - - - -3.87M
Other cashflows from financing activities -2.92M -0.23M -1.43M -0.08M 1.02M
Change to netincome - - - - 1.15M
Capital expenditures 0.12M 1.27M 1.50M 2.91M 1.13M
Change in working capital -0.03M -0.44M -0.07M -1.92M -1.99M
Stock based compensation - - 1.27M 1.46M 1.01M
Other non cash items 1.26M -24.30M 0.55M -0.38M 0.84M
Free cash flow -32.29M -26.01M -27.25M -28.48M -18.68M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PEB
Pacific Edge Ltd		 -0.02
8.51%		 0.21 - - 18.13 27.58 24.27 -7.86
SHL
Sonic Healthcare Ltd		 0.09
0.45%		 19.92 16.16 17.21 0.90 1.15 1.36 8.10
IDX
Integral Diagnostics Ltd		 -
-%		 1.70 28.83 15.24 0.82 0.97 1.52 9.49
ACL
Australian Clinical Labs Ltd		 0.01
0.30%		 3.33 26.67 16.84 0.81 3.95 1.24 5.12
HLS
Healius Ltd		 0.01
2.86%		 0.54 - 29.24 0.26 2.08 0.94 10.14

Profile*

Pacific Edge Ltd

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients; Cxbladder Detect, which improve practice workflow and efficiency in urological care; Cxbladder Triage Plus, a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in patients; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a recurrent non-muscle invasive bladder cancer. In addition, the company is developing products for bladder, gastric, colorectal and endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Centre for Innovation, Dunedin, New Zealand, 9016

64 3 577 6733

https://www.pacificedgedx.com

Name Title Year Born
Dr. Peter Meintjes Chief Exec. Officer NA
Mr. Grant Gibson Chief Financial Officer NA
Mr. Darrell Morgan Chief Operating Officer NA
Dr. Justin Harvey Chief Technology Officer NA
Prof. Parry Guilford Ph.D. Chief Scientific Officer & Member of Scientific Advisory Board NA
Mr. Jack Atchason Sr. VP of Sales - Pacific Edge Diagnostics USA Limited NA
Mr. Andrew McIntosh Chief Digital Officer NA
Mr. David Levison Exec. Chairman & Pres of Pacific Edge Diagnostics USA 1960
Dr. Peter Meintjes Chief Executive Officer NA
Mr. Jack Atchason Senior Vice President of Sales - Pacific Edge Diagnostics USA Limited NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…